Treatment Burden

“I wanted a treatment that was designed to treat patients for a longer time. When your patients ask, answer and act.”

— Jessica D. McCluskey, MD

Results presented below are from a single case; results may vary.

Jessica D. McCluskey, MD

Board-certified ophthalmologist and fellowship-trained retina specialist at Thomas Eye Group, a large multispecialty ophthalmology practice.

Academic affiliations:

  • Medical School at the University of Mississippi – received Awards in Excellence in the fields of ophthalmology and neurosurgery
  • Four-year ophthalmology residency at the University of Mississippi where she served as chief resident
  • Two-year retina fellowship at the University of Texas Southwestern Medical Center

Patient profile1

Sex: Female
Age: 73
Diagnosis: DME
Treated eye: OS
Concomitant conditions:
• High blood pressure
• Hypercholesterolemia
• Proliferative diabetic retinopathy with 2 panretinal photocoagulations
Treatment history:
• 2X Focal laser
• 8X Anti-VEGF
• 6X Corticosteroid
Notes: Pseudophakic

Reasons Dr. McCluskey chose ILUVIEN:

  • Patient history of monthly injections over the course of 6 years
  • Missed injections negatively impacted patient’s vision
  • Interested in an alternative to monthly injections

Patient outcome

  • Vision was maintained over 1 year of follow-up
  • Good CST reduction and maintenance
  • IOP stable
  • No further treatment was needed during the 15-month follow-up period

“This patient received monthly DME injections for years and after the ILUVIEN injection, she has not had another injection in 16 months. That’s a huge success for my patient.”

— Jessica D. McCluskey, MD

Retinal thickness (μm)

Best corrected visual acuity (BCVA)

Intraocular pressure (IOP)

Selected OCT Scans

Baseline

ILUVIEN injected
Visual Acuity: 20/40
Letters: 70
OCT: 485 μm
IOP: 14 mm Hg

TREATMENTBURDEN CASE
TREATMENT
BURDEN CASE

Download a printable, pdf version of this case.

TREATMENTBURDEN DATA
TREATMENT
BURDEN DATA

See how ILUVIEN reduced treatment burden
in the real-world USER Study.